FRONTEO : and Axcelead DDP sign basic AI drug discovery support partnership agreement

　FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President and CEO: Masahiro Morimoto, hereinafter referred to as FRONTEO) and Axcelead Drug Discovery Partners Co., Ltd. (Headquarters: Fujisawa City, Kanagawa Prefecture, President and CEO: Nobuhiko Yamada, hereinafter referred to as Axcelead DDP), We would like to inform you that we have concluded a basic AI drug discovery support partnership agreement.

　In its "Drug Discovery AI Factory" business, FRONTEO provides services that support the efficiency, acceleration, and success rate of drug discovery by utilizing proprietary AI specialized in hypothesis generation for drug research and development. doing. Axcelead DDP possesses the platform functions necessary for drug discovery, and utilizes them to support drug discovery research by a variety of drug discovery players, including pharmaceutical companies, bioventures, academia, and government research institutions. By signing this basic partnership agreement, FRONTEO's hypothesis generation AI and Axcelead DDP's drug discovery platform functions will be combined to create hypotheses through dry research (data analysis using computers and AI) and wet research (cell, animal, etc.). This makes it possible to efficiently operate the cycle of verifying these results using biological tests (using biological tests).

　Hiroyoshi Toyoshiba, FRONTEO's executive officer and CTO, said, ``As we move forward with our Drug Discovery AI Factory business, our client companies entrust us with the next step, wet research, to verify the hypotheses we derived from our dry research. We have received many requests to do this.By signing a basic partnership agreement with Axcelead DDP, we will meet customer needs and further contribute to the development of customer companies' drug discovery research and business and the improvement of the quality of medical care. I'm happy to be able to do this."

　Masayuki Ii, CSO of Axcelead DDP, said, ``We are pleased to be able to further strengthen our AI drug discovery support business through this partnership with FRONTEO, which has strengths in data analysis using hypothesis generation AI. By conducting wet research on hypotheses based on the drug discovery research capabilities that we have cultivated, we will be able to accelerate our customers' drug discovery research more than ever. As a platform company, we will continue to contribute to the creation of innovative new drugs for our customers."

■About Axcelead DDP　URL: https://www.axcelead.com/
Axcelead DDP is Japan's first drug discovery solution provider that started business in July 2017 by taking over Takeda Pharmaceutical Company Limited's drug discovery platform business. is. It has almost all the functions necessary for drug discovery, and provides one-stop non-clinical drug discovery research services, from searching for drug discovery targets to optimizing drug candidate compounds, and even bridging processes to clinical development. .

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO is a data analysis company that provides various AI solutions and services using the in-house developed AI engine "KIBIT". Based on the philosophy of "providing solutions that do not overlook risks and opportunities buried in records and realizing fairness in the information society," extract meaningful and important information from vast amounts of text data and complex networks. Our strengths are natural language processing and network analysis technologies that support advanced judgments by experts.We are developing businesses in the areas of legal tech AI, business intelligence, life science AI, and economic security, and contributing to solving various corporate and social issues. Founded in August 2003, listed on Tokyo Stock Exchange Mothers (currently Tokyo Stock Exchange Growth) on June 8, 2007.The company operates in Japan, the United States, South Korea, and Taiwan.Acquisition of first-class medical device manufacturing and sales business license, notification of controlled medical device sales business.Capital 6 thousand yen (as of March 26, 3,042,317).

※FRONTEO、KIBIT、Drug Discovery AI FactoryはFRONTEOの日本における登録商標です。